Thursday, 5 November 2026European Markets

INTEROIL EXPL PROD Stock 16.79% Up On Monday

Loading stream...

(VIANEWS) - The Market ended the session with INTEROIL EXPL PROD (IOX.OL) rising 16.79% to kr8.90 on Monday while Oslo Børs Benchmark Index_GI jumped 0.72% to kr1,417.06.

INTEROIL EXPL PROD's last close was kr7.62, 30.73% under its 52-week high of kr11.00.

About INTEROIL EXPL PROD

Interoil Exploration and Production ASA, together with its subsidiaries, operates as an upstream oil exploration and production company in Argentina and Colombia. It engages in the acquisition, exploration, development, and operation of oil and natural gas properties. The company's portfolio includes two producing concessions and two exploration concessions in Colombia; and one exploration and seven production concessions in Argentina. Interoil Exploration and Production ASA was incorporated in 2005 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, INTEROIL EXPL PROD has a trailing twelve months EPS of kr0.03.

PE Ratio

INTEROIL EXPL PROD has a trailing twelve months price to earnings ratio of 296.6. Meaning, the purchaser of the share is investing kr296.6 for every norwegian krone of annual earnings.

More news about INTEROIL EXPL PROD (IOX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com
INTEROIL EXPL PROD Stock 16.79% Up On Monday | ViaNews EU